Apalutamide, a drug belonging to the androgen receptor inhibitor class, has become a cornerstone therapy for prostate cancer. But researchers aren't stopping there. Clinical trials are actively exploring apalutamide's potential in new and exciting ways. Let's delve into the latest advancements and future directions in apalutamide research. Current Landscape: Proven Benefits in Prostate Cancer...